Deutsche Bank AG Buys 12,060 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Deutsche Bank AG boosted its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 7.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 169,323 shares of the company's stock after acquiring an additional 12,060 shares during the period. Deutsche Bank AG owned 0.35% of Mirum Pharmaceuticals worth $7,002,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. Price T Rowe Associates Inc. MD boosted its holdings in shares of Mirum Pharmaceuticals by 10.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,422,729 shares of the company's stock worth $58,831,000 after purchasing an additional 138,623 shares during the period. Geode Capital Management LLC raised its position in Mirum Pharmaceuticals by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 943,344 shares of the company's stock valued at $39,016,000 after purchasing an additional 7,147 shares during the last quarter. Clearbridge Investments LLC raised its position in Mirum Pharmaceuticals by 2.0% during the 4th quarter. Clearbridge Investments LLC now owns 907,317 shares of the company's stock valued at $37,518,000 after purchasing an additional 18,217 shares during the last quarter. Lord Abbett & CO. LLC lifted its holdings in Mirum Pharmaceuticals by 5.5% in the 4th quarter. Lord Abbett & CO. LLC now owns 782,354 shares of the company's stock worth $32,350,000 after buying an additional 40,986 shares during the period. Finally, Boone Capital Management LLC lifted its holdings in Mirum Pharmaceuticals by 7.0% in the 4th quarter. Boone Capital Management LLC now owns 581,843 shares of the company's stock worth $24,059,000 after buying an additional 38,000 shares during the period.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on MIRM. Raymond James reissued a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research note on Tuesday, May 13th. HC Wainwright reissued a "buy" rating and set a $73.00 price objective on shares of Mirum Pharmaceuticals in a research report on Monday. JMP Securities upped their price objective on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a report on Friday, May 9th. Finally, Robert W. Baird lifted their target price on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a research note on Thursday, February 27th. Ten research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $60.73.

Insider Buying and Selling

In related news, SVP Jolanda Howe sold 57,606 shares of the company's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.35, for a total transaction of $2,554,826.10. Following the completion of the transaction, the senior vice president now owns 4,841 shares in the company, valued at approximately $214,698.35. This represents a 92.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Christopher Peetz sold 27,279 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $44.21, for a total transaction of $1,206,004.59. Following the transaction, the chief executive officer now directly owns 138,641 shares of the company's stock, valued at $6,129,318.61. This trade represents a 16.44% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 92,764 shares of company stock worth $4,109,161 in the last three months. Insiders own 14.36% of the company's stock.

Mirum Pharmaceuticals Stock Down 2.3%

NASDAQ MIRM traded down $1.03 during trading hours on Wednesday, reaching $44.31. 322,751 shares of the company's stock traded hands, compared to its average volume of 523,496. Mirum Pharmaceuticals, Inc. has a 52-week low of $23.83 and a 52-week high of $54.23. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The firm has a 50-day simple moving average of $42.97 and a 200 day simple moving average of $44.55. The firm has a market cap of $2.19 billion, a PE ratio of -21.94 and a beta of 0.95.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business had revenue of $111.59 million during the quarter, compared to the consensus estimate of $98.47 million. During the same quarter last year, the firm earned ($0.54) earnings per share. The business's revenue for the quarter was up 61.2% on a year-over-year basis. Sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.